항체 생산 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antibody Production Market size is expected to reach USD 53.30 Billion in 2034 from USD 25.98 Billion (2025) growing at a CAGR of 8.31% during 2026-2034.

The Global Antibody Production market is experiencing significant growth due to the expanding pipeline of monoclonal antibodies across oncology, autoimmune diseases, and infectious disorders. Increasing regulatory approvals and biosimilar development have intensified manufacturing demand. Expansion of biologics facilities and greater outsourcing to contract development and manufacturing organizations (CDMOs) are supporting production scale-up and enhancing global supply capabilities.

Major growth drivers include advancements in cell line engineering, process intensification technologies, and single-use bioreactor systems that improve yield and reduce production costs. Rising demand for antibody-based diagnostics and research reagents further strengthens revenue generation. Additionally, increased investment in biosimilars and complex antibody formats, such as bispecific antibodies, is accelerating innovation and competitive activity within the sector.

Looking ahead, the market is poised for sustained expansion with the commercialization of antibody-drug conjugates and next-generation biologics. Continuous manufacturing, modular facilities, and digitalized quality control systems will streamline operations and reduce time-to-market. Emerging economies are expected to play a critical role in capacity expansion, while regulatory harmonization will facilitate broader global distribution.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Antibody Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Antibody Types

By Process

• Upstream Processing
• Downstream Processing
• Filtration

By End-user

• Pharmaceutical and Biotechnology Companies
• Research Laboratories
• Other End-users

COMPANIES PROFILED

• Danaher Corporation, Merck KGaA, Sartorius, Thermo Fisher Scientific Inc, Eppendorf AG, INTEGRA Biosciences AG, Genetix Biotech Asia Pvt Ltd, Solaris Biotech, Grifols, F HoffmannLa Roche AG, FiberCell Systems Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY PRODUCTION MARKET: BY ANTIBODY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Antibody Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Polyclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Antibody Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY PRODUCTION MARKET: BY PROCESS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Process
• 5.2. Upstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Downstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Filtration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY PRODUCTION MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other End-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Antibody Type
  • 7.2.2 By Process
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Antibody Type
  • 7.3.2 By Process
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Antibody Type
  • 7.4.2 By Process
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Antibody Type
  • 7.5.2 By Process
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Antibody Type
  • 7.6.2 By Process
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTIBODY PRODUCTION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Danaher Corporation
  • 9.2.2 Merck KGaA
  • 9.2.3 Sartorius
  • 9.2.4 Thermo Fisher Scientific Inc
  • 9.2.5 Eppendorf AG
  • 9.2.6 INTEGRA Biosciences AG
  • 9.2.7 Genetix Biotech Asia Pvt Ltd
  • 9.2.8 Solaris Biotech
  • 9.2.9 Grifols
  • 9.2.10 F. Hoffmann-La Roche AG
  • 9.2.11 FiberCell Systems Inc